Soleno Therapeutics to Participate in Upcoming September Conferences
Rhea-AI Summary
Soleno Therapeutics (NASDAQ: SLNO), a biopharmaceutical company focused on rare disease therapeutics, has announced its participation in five major healthcare investor conferences during September 2025.
The company will present at the Cantor Global Healthcare Conference (Sept 3), Wells Fargo Healthcare Conference (Sept 4), H.C. Wainwright Global Investment Conference (Sept 8), Baird Global Healthcare Conference (Sept 9), and Bernstein Healthcare Forum (Sept 25). All presentations will be in fireside chat format.
Webcasts for the Cantor and Wells Fargo events will be available for replay on Soleno's website.
Positive
- None.
Negative
- None.
REDWOOD CITY, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will participate in the following investor conferences in September:
Cantor Global Healthcare Conference
Presentation Date: Wednesday, September 3, 2025 at 1:00 PM ET
Presentation Format: Fireside Chat
Webcast: Here
Wells Fargo Healthcare Conference
Presentation Date: Thursday, September 4, 2025 at 1:30 PM ET
Presentation Format: Fireside Chat
Webcast: Here
H.C. Wainwright 27th Annual Global Investment Conference
Presentation Date: Monday, September 8, 2025 at 4:00 PM ET
Presentation Format: Fireside Chat
Baird Global Healthcare Conference
Presentation Date: Tuesday, September 9, 2025 at 2:00 PM ET
Presentation Format: Fireside Chat
Bernstein 2nd Annual Healthcare Forum
Presentation Date: Thursday, September 25, 2025 at 9:40 AM ET
Presentation Format: Fireside Chat
Replays of the Cantor and Wells Fargo events will be available in the Investors section on the Company’s website at www.soleno.life.
About Soleno Therapeutics, Inc.
Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The Company’s first commercial product, VYKAT™ XR (diazoxide choline) extended-release tablets, formerly known as DCCR, is a once-daily oral treatment for hyperphagia in adults and children 4 years of age and older with Prader-Willi syndrome. For more information, please visit www.soleno.life.
Corporate Contact:
Brian Ritchie
LifeSci Advisors, LLC
212-915-2578
FAQ
When is Soleno Therapeutics (SLNO) presenting at the Cantor Global Healthcare Conference 2025?
How many investor conferences will Soleno Therapeutics (SLNO) attend in September 2025?
Where can investors access Soleno Therapeutics' (SLNO) conference presentations?
What is the format of Soleno Therapeutics' (SLNO) conference presentations?
